Organogenesis (NASDAQ:ORGO) Price Target Cut to $2.00 by Analysts at Truist Financial

Organogenesis (NASDAQ:ORGO) had its price target trimmed by Truist Financial from $3.00 to $2.00 in a research report sent to investors on Friday, MarketBeat reports. The brokerage currently has a hold rating on the stock.

Other equities analysts also recently issued reports about the stock. UBS Group set a $3.00 price target on shares of Organogenesis in a report on Thursday, May 28th. Weiss Ratings lowered shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. BTIG Research cut shares of Organogenesis from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Organogenesis from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $4.33.

Organogenesis Stock Performance

Shares of Organogenesis stock opened at $1.86 on Friday. The business’s fifty day simple moving average is $2.42 and its 200 day simple moving average is $2.76. The firm has a market capitalization of $239.34 million, a P/E ratio of -2.16 and a beta of 1.34. Organogenesis has a 12 month low of $1.54 and a 12 month high of $7.08. The company has a current ratio of 3.53, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.36). Organogenesis had a negative net margin of 19.94% and a negative return on equity of 21.24%. The business had revenue of $43.76 million during the quarter, compared to the consensus estimate of $54.27 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ORGO. BlackRock Inc. bought a new stake in Organogenesis in the 2nd quarter valued at about $17,616,000. First Light Asset Management LLC purchased a new position in shares of Organogenesis in the second quarter worth about $24,804,000. Deutsche Bank AG raised its position in shares of Organogenesis by 0.4% in the fourth quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock valued at $17,082,000 after purchasing an additional 13,301 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Organogenesis by 5.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock valued at $6,851,000 after buying an additional 160,026 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Organogenesis by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock worth $9,259,000 after buying an additional 62,346 shares during the period. Institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.